Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
Immune cell therapy takes on rare Muscle-Weakening disease
Disease control Recruiting nowThis study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard drugs for generalized myasthenia gravis. The goal is to see if this one-time cell therapy can better control symptoms like muscle weakness and fatigue. About 66 adults who ha…
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 17, 2026 00:31 UTC
-
15-Year safety check for experimental CAR t therapy begins
Knowledge-focused Recruiting nowThis study tracks 70 people who have already received an infusion of KYV-101, a CAR T cell therapy, for autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal is to watch for delayed side effects, new cancers, or other health problems over up to 15…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC